PF-Atlas › Clinical Trials › NCT05636774

Empower the Heart of Patients With Terminal Cancer Using Cardiac Medicines Trial

Heart failure medication · Not specified

Registry ID
NCT05636774
Phase
Not specified
Status
Completed
Drug / intervention
Heart failure medication
Sponsor
University Hospital, Essen
Start
2022-12-12
Enrollment
97
Locations
1

About this trial

The pathophysiological implications of various cancer diseases and anti-cancer therapies is the occurrence of a cardiac disease-like phenotype with cardiac dysfunction, cardiac wasting, and cardiac homeostasis changes (incl. fibrosis and apoptosis) in end-stage cancer patients, causing heart failure like syndrome with development of congestion, dyspnoea and severely reduced physical functioning. The present trial aims to evaluate, if a heart failure medication improves the self-care ability and self-reported health care status of patients with with advanced cancer receiving specialized palliative care.

View NCT05636774 on ClinicalTrials.gov →

Explore related

All Heart failure medication trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT05636774 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.